This prompted us to test the PTEN/PI3K/AKT signaling pathway on RB/E2F apoptosis suppression in vivo, which can block RB/E2F-induced cell death in tissue culture models, to ascertain if the PI3K pathway may provide a potential avenue for retinoblastoma treatment [15,16]. The gene discussed is AKT1; the disease is retinoblastoma.